Ignite Creation Date:
2025-12-24 @ 2:17 PM
Ignite Modification Date:
2026-01-11 @ 12:24 AM
Study NCT ID:
NCT06012695
Status:
RECRUITING
Last Update Posted:
2024-11-14
First Post:
2023-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Sponsor:
Novelwise Pharmaceutical Corporation
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
NBM-BMX-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None